Home / Health / US Patent Fuels Endometriosis Blood Test
US Patent Fuels Endometriosis Blood Test
8 Jul
Summary
- US patent granted for innovative endometriosis blood test.
- Test could significantly shorten diagnosis time for affected women.
- Company aims for commercial traction with a capital-light model.
Proteomics International Laboratories has achieved a significant milestone with the granting of a US patent for its PromarkerEndo blood test. This novel diagnostic tool targets endometriosis, a condition impacting one in nine women, which frequently endures a lengthy and invasive diagnostic process. The United States Patent and Trademark Office (USPTO) issued the patent, providing protection until March 2041 and establishing a crucial foothold in the substantial US healthcare market.
This patent signifies a strategic shift for the Perth-based company, moving from an extensive research phase toward commercialization. Under new leadership, Proteomics is implementing a disciplined three-year plan to transform its scientific platform into a scalable diagnostics business. The company is adopting a capital-light strategy, relying on distribution partners to expedite market entry and enhance capital efficiency.
Beyond PromarkerEndo, Proteomics has a portfolio of other diagnostic tests. These include PromarkerD for predicting diabetes-related kidney disease, PromarkerEso for assessing throat cancer risk, and OxiDx for oxidative stress testing. The company's roadmap includes appointing an Australian distributor and launching local market releases for PromarkerEndo by the first half of fiscal 2027, followed by US distribution and reimbursement submissions by the second half.
